fluorouracil has been researched along with Common Bile Duct Neoplasms in 49 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma." | 3.79 | Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. ( Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA, 2013) |
| "Three patients with metastatic carcinoma of the ampulla of Vater received celiac artery infusion of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin followed by intravenous administration of the same combination." | 3.67 | Combination chemotherapy for metastatic carcinoma of the ampulla of Vater--report of three cases. ( Bukowski, RM; Hermann, RE; Theodors, A, 1984) |
| "Nineteen patients with unresectable and metastatic adenocarcinoma of the pancreas and ampulla of Vater were treated with intermittent regional infusion of the celiac axis (CAI) with the combination of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S)." | 3.66 | Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. ( Bukowski, RM; Hewlett, JS; Livingston, RB; Theodors, A; Weick, JK, 1982) |
| "In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0." | 2.73 | Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. ( Hermans, JJ; Hop, WC; Incrocci, L; Jeekel, J; Kazemier, G; Morak, MJ; van Dekken, H; van der Gaast, A; van Eijck, CH, 2008) |
| "The role of adjuvant chemoradiation in pancreatic cancer remains unclear." | 2.73 | Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. ( Debois, M; Erdmann, J; Hop, WC; Jeekel, J; Klinkenbijl, JH; Smeenk, HG; Tran, KC; van Cutsem, E; van Dekken, H; van Eijck, CH, 2007) |
| "Pancreatic cancer has a dismal prognosis." | 1.38 | Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. ( Dicheva, BM; Eggermont, AM; Hop, WC; Koning, GA; Seynhaeve, AL; Ten Hagen, TL; van Dekken, H; van der Zee, JA; van Eijck, CH, 2012) |
| "Nine of these 18 patients had bile duct cancer, seven had gallbladder cancer, and two had cancer of the papilla of Vater." | 1.32 | [Adjuvant arterial infusion chemotherapy for patients with biliary cancer]. ( Hasuike, Y; Kashiwazaki, M; Takeda, Y; Tsujinaka, T, 2004) |
| "Preoperative chemoradiation for pancreatic cancer is associated with low rates of hepatic toxicity and biliary stent-related complications." | 1.31 | Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. ( Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 2000) |
| " There were two EBRT dosage groups: Low EBRT, 23." | 1.30 | Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Grochow, LB; Haulk, TL; Hruban, RH; Lillemoe, KD; Ord, S; Pitt, HA; Sohn, TA; Yeo, CJ; Zahurak, ML, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.16) | 18.7374 |
| 1990's | 3 (6.12) | 18.2507 |
| 2000's | 19 (38.78) | 29.6817 |
| 2010's | 21 (42.86) | 24.3611 |
| 2020's | 2 (4.08) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, J | 1 |
| Lee, W | 1 |
| Shin, J | 1 |
| Park, Y | 1 |
| Kwon, JW | 1 |
| Jun, E | 1 |
| Song, KB | 1 |
| Lee, JH | 1 |
| Hwang, DW | 1 |
| Park, SY | 1 |
| Kim, SC | 1 |
| Xu, H | 1 |
| Chai, CP | 1 |
| Miao, X | 1 |
| Tang, H | 1 |
| Hu, JJ | 1 |
| Zhang, H | 1 |
| Zhou, WC | 1 |
| Jin, Z | 1 |
| Hartgers, ML | 1 |
| Sanhueza, CT | 1 |
| Shubert, CR | 1 |
| Alberts, SR | 1 |
| Truty, MJ | 1 |
| Muppa, P | 1 |
| Nagorney, DM | 1 |
| Smyrk, TC | 1 |
| Hassan, M | 1 |
| Mahipal, A | 1 |
| Ecker, BL | 1 |
| Vollmer, CM | 1 |
| Behrman, SW | 1 |
| Allegrini, V | 1 |
| Aversa, J | 1 |
| Ball, CG | 1 |
| Barrows, CE | 1 |
| Berger, AC | 2 |
| Cagigas, MN | 1 |
| Christein, JD | 1 |
| Dixon, E | 1 |
| Fisher, WE | 1 |
| Freedman-Weiss, M | 1 |
| Guzman-Pruneda, F | 1 |
| Hollis, RH | 1 |
| House, MG | 1 |
| Kent, TS | 1 |
| Kowalsky, SJ | 1 |
| Malleo, G | 1 |
| Salem, RR | 1 |
| Salvia, R | 1 |
| Schmidt, CR | 1 |
| Seykora, TF | 1 |
| Zheng, R | 1 |
| Zureikat, AH | 1 |
| Dickson, PV | 1 |
| Nichols, RC | 1 |
| George, TJ | 1 |
| Zaiden, RA | 1 |
| Awad, ZT | 1 |
| Asbun, HJ | 1 |
| Huh, S | 1 |
| Ho, MW | 1 |
| Mendenhall, NP | 1 |
| Morris, CG | 1 |
| Hoppe, BS | 1 |
| Kim, HS | 1 |
| Shin, SJ | 1 |
| Kim, JH | 1 |
| Kim, H | 1 |
| Choi, HJ | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Comsulea, M | 1 |
| Kadar, Z | 1 |
| Azamfirei, L | 1 |
| Molnar, C | 1 |
| Shoji, H | 1 |
| Morizane, C | 1 |
| Hiraoka, N | 1 |
| Kondo, S | 1 |
| Ueno, H | 1 |
| Ohno, I | 1 |
| Shimizu, S | 1 |
| Mitsunaga, S | 1 |
| Ikeda, M | 1 |
| Okusaka, T | 1 |
| Kim, K | 4 |
| Chie, EK | 4 |
| Jang, JY | 5 |
| Kim, SW | 4 |
| Han, SW | 2 |
| Oh, DY | 4 |
| Im, SA | 4 |
| Kim, TY | 4 |
| Bang, YJ | 4 |
| Ha, SW | 4 |
| Senatore, FJ | 1 |
| Ynson, ML | 1 |
| Dasanu, CA | 1 |
| Colussi, O | 1 |
| Voron, T | 1 |
| Pozet, A | 1 |
| Hammel, P | 1 |
| Sauvanet, A | 1 |
| Bachet, JB | 1 |
| Vaillant, JC | 1 |
| Rougier, P | 1 |
| Nordlinger, B | 1 |
| Berger, A | 1 |
| Coriat, R | 1 |
| Dousset, B | 1 |
| Malka, D | 1 |
| André, T | 1 |
| Paye, F | 1 |
| Aparicio, T | 1 |
| Locher, C | 1 |
| Cojean Zeleck, D | 1 |
| Tchinou, L | 1 |
| Bonnetain, F | 1 |
| Taieb, J | 1 |
| Giuliani, J | 1 |
| Piacentini, P | 1 |
| Bonetti, A | 1 |
| Morak, MJ | 1 |
| van der Gaast, A | 1 |
| Incrocci, L | 1 |
| van Dekken, H | 3 |
| Hermans, JJ | 1 |
| Jeekel, J | 3 |
| Hop, WC | 3 |
| Kazemier, G | 1 |
| van Eijck, CH | 3 |
| Komatsu, S | 1 |
| Sonoyama, T | 1 |
| Ochiai, T | 1 |
| Ichikawa, D | 1 |
| Ikoma, H | 1 |
| Okamura, H | 1 |
| Otsuji, E | 1 |
| Overman, MJ | 1 |
| Varadhachary, GR | 1 |
| Kopetz, S | 1 |
| Adinin, R | 1 |
| Lin, E | 1 |
| Morris, JS | 1 |
| Eng, C | 1 |
| Abbruzzese, JL | 2 |
| Wolff, RA | 3 |
| Kim, ST | 1 |
| Lee, J | 1 |
| Lee, KT | 1 |
| Lee, JK | 1 |
| Lee, KH | 1 |
| Choi, SH | 1 |
| Heo, JS | 1 |
| Choi, DW | 1 |
| Park, SH | 1 |
| Park, JO | 1 |
| Lim, HY | 1 |
| Park, YS | 1 |
| Kang, WK | 1 |
| Louvet, C | 1 |
| Tournigand, C | 1 |
| Yovino, S | 1 |
| Poppe, M | 1 |
| Jabbour, S | 1 |
| David, V | 1 |
| Garofalo, M | 1 |
| Pandya, N | 1 |
| Alexander, R | 1 |
| Hanna, N | 1 |
| Regine, WF | 1 |
| Kang, SP | 1 |
| Saif, MW | 1 |
| Showalter, TN | 1 |
| Zhan, T | 1 |
| Anne, PR | 1 |
| Chervoneva, I | 1 |
| Mitchell, EP | 1 |
| Yeo, CJ | 3 |
| Rosato, EL | 1 |
| Kennedy, EP | 1 |
| Song, BJ | 1 |
| Kwon, JH | 1 |
| Kim, JJ | 1 |
| Lee, JW | 1 |
| Min, SY | 1 |
| Lee, KB | 1 |
| Ryu, JK | 1 |
| Narang, AK | 1 |
| Miller, RC | 2 |
| Hsu, CC | 1 |
| Bhatia, S | 3 |
| Pawlik, TM | 1 |
| Laheru, D | 1 |
| Hruban, RH | 3 |
| Zhou, J | 1 |
| Winter, JM | 1 |
| Haddock, MG | 2 |
| Donohue, JH | 2 |
| Schulick, RD | 1 |
| Wolfgang, CL | 1 |
| Cameron, JL | 3 |
| Herman, JM | 1 |
| van der Zee, JA | 1 |
| Dicheva, BM | 1 |
| Seynhaeve, AL | 1 |
| Koning, GA | 1 |
| Eggermont, AM | 1 |
| Ten Hagen, TL | 1 |
| Neoptolemos, JP | 1 |
| Moore, MJ | 1 |
| Cox, TF | 1 |
| Valle, JW | 1 |
| Palmer, DH | 1 |
| McDonald, AC | 1 |
| Carter, R | 1 |
| Tebbutt, NC | 1 |
| Dervenis, C | 1 |
| Smith, D | 1 |
| Glimelius, B | 1 |
| Charnley, RM | 1 |
| Lacaine, F | 1 |
| Scarfe, AG | 1 |
| Middleton, MR | 1 |
| Anthoney, A | 1 |
| Ghaneh, P | 1 |
| Halloran, CM | 1 |
| Lerch, MM | 1 |
| Oláh, A | 1 |
| Rawcliffe, CL | 1 |
| Verbeke, CS | 1 |
| Campbell, F | 1 |
| Büchler, MW | 1 |
| Takada, T | 1 |
| Amano, H | 1 |
| Yasuda, H | 1 |
| Nimura, Y | 1 |
| Matsushiro, T | 1 |
| Kato, H | 1 |
| Nagakawa, T | 1 |
| Nakayama, T | 1 |
| Nabeshima, S | 1 |
| Kishihara, Y | 1 |
| Nabeshima, A | 1 |
| Yamaga, S | 1 |
| Kinjo, M | 1 |
| Kashiwagi, S | 1 |
| Hayashi, J | 1 |
| Sorio, C | 1 |
| Moore, PS | 1 |
| Ennas, MG | 1 |
| Tecchio, C | 1 |
| Bonora, A | 1 |
| Sartoris, S | 1 |
| Balzarini, P | 1 |
| Grigolato, P | 1 |
| Scarpa, A | 1 |
| Takeda, Y | 1 |
| Hasuike, Y | 1 |
| Kashiwazaki, M | 1 |
| Tsujinaka, T | 1 |
| Sikora, SS | 1 |
| Balachandran, P | 1 |
| Dimri, K | 1 |
| Rastogi, N | 1 |
| Kumar, A | 1 |
| Saxena, R | 1 |
| Kapoor, VK | 1 |
| O'Connor, JK | 1 |
| Sause, WT | 1 |
| Hazard, LJ | 1 |
| Belnap, LP | 1 |
| Noyes, RD | 1 |
| Chang, PY | 1 |
| Chao, TY | 1 |
| Dai, MS | 1 |
| Krishnan, S | 2 |
| Hughes, MA | 1 |
| Frassica, DA | 1 |
| Riall, TS | 1 |
| Lillemoe, KD | 2 |
| Donehower, RC | 1 |
| Laheru, DA | 1 |
| Abrams, RA | 2 |
| Smeenk, HG | 1 |
| Erdmann, J | 1 |
| Tran, KC | 1 |
| Debois, M | 1 |
| van Cutsem, E | 1 |
| Klinkenbijl, JH | 1 |
| Noda, T | 1 |
| Ohigashi, H | 1 |
| Ishikawa, O | 1 |
| Eguchi, H | 1 |
| Yamada, T | 1 |
| Sasaki, Y | 1 |
| Yano, M | 1 |
| Imaoka, S | 1 |
| Rana, V | 1 |
| Evans, DB | 2 |
| Varadhachary, G | 1 |
| Das, P | 1 |
| Delclos, ME | 1 |
| Janjan, NA | 2 |
| Crane, CH | 2 |
| Pisters, PW | 2 |
| Theodors, A | 2 |
| Bukowski, RM | 2 |
| Hewlett, JS | 1 |
| Livingston, RB | 1 |
| Weick, JK | 1 |
| Hermann, RE | 1 |
| Recchia, F | 1 |
| Recchia, G | 1 |
| Tempesti, M | 1 |
| Venditti, A | 1 |
| Ishikawa, T | 1 |
| Ishikawa, N | 2 |
| Oota, H | 1 |
| Yoshida, T | 1 |
| Honma, A | 1 |
| Kamimura, T | 1 |
| Takeda, K | 1 |
| Ozaki, T | 1 |
| Grochow, LB | 1 |
| Chakravarthy, A | 1 |
| Sohn, TA | 1 |
| Zahurak, ML | 1 |
| Haulk, TL | 1 |
| Ord, S | 1 |
| Pitt, HA | 1 |
| Hudec, WA | 1 |
| Lee, JE | 1 |
| Raijman, I | 1 |
| Lahoti, S | 1 |
| Rich, TA | 1 |
| Lenzi, R | 1 |
| Mehta, VK | 1 |
| Fisher, GA | 1 |
| Ford, JM | 1 |
| Poen, JC | 1 |
| Vierra, MA | 1 |
| Oberhelman, HA | 1 |
| Bastidas, AJ | 1 |
| Bouras, N | 1 |
| Caudry, M | 1 |
| Saric, J | 1 |
| Bonnel, C | 1 |
| Rullier, E | 1 |
| Trouette, R | 1 |
| Demeaux, H | 1 |
| Maire, JP | 1 |
| Suda, Y | 1 |
| Akazawa, S | 1 |
| Splinter, TA | 1 |
| Obertop, H | 1 |
| Kok, TC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater[NCT00354887] | Phase 2 | 31 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. A Pan-European Prospective Multicenter Double Single Arm Cohort Study.[NCT06068023] | 400 participants (Anticipated) | Observational | 2023-07-01 | Recruiting | |||
| A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150] | Phase 2/Phase 3 | 231 participants (Anticipated) | Interventional | 2020-01-05 | Recruiting | ||
| European Study Group For Pancreatic Cancer - Trial 3[NCT00058201] | Phase 3 | 1,030 participants (Anticipated) | Interventional | 2001-07-31 | Completed | ||
| Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Randomized Controlled Trial Comparing Adjuvant Chemotherapy Vs. no Chemotherapy for Patients With Carcinoma of Gallbladder Undergoing Curative Resection.[NCT02778308] | 100 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer[NCT03167112] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-03 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR. (NCT00354887)
Timeframe: Every 9 weeks from treatment initiation and confirmatory images 6 weeks or more after initial responses
| Intervention | participants (Number) | |
|---|---|---|
| Participants with CR | Participants with PR | |
| Oxaliplatin + Capecitabine | 3 | 12 |
1 review available for fluorouracil and Common Bile Duct Neoplasms
| Article | Year |
|---|---|
Adenocarcinoma of the ampulla of Vater: what treatment options are available?
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy | 2015 |
7 trials available for fluorouracil and Common Bile Duct Neoplasms
41 other studies available for fluorouracil and Common Bile Duct Neoplasms
| Article | Year |
|---|---|
Controversial benefit of 5-fluorouracil/leucovorin-based adjuvant chemotherapy for ampullary cancer: a propensity score-matched analysis.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Common Bil | 2022 |
Establishment and characterization of a new human ampullary carcinoma cell line, DPC-X1.
Topics: Ampulla of Vater; Animals; Carcinoembryonic Antigen; Cell Line; Cell Line, Tumor; Common Bile Duct N | 2023 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antin | 2018 |
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant | 2019 |
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Commo | 2013 |
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2014 |
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad | 2016 |
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecit | 2015 |
Long-term complete response of multiple hepatic metastases from carcinoma of the papilla of Vater using intrahepatic infusion of 5-FU with low-dose cisplatin following pancreaticoduodenectomy.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Thera | 2008 |
Role of adjuvant chemoradiotherapy for ampulla of Vater cancer.
Topics: Adult; Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2009 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec | 2010 |
Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Ad | 2010 |
Time to move to targeted drugs in biliary tract cancer?
Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemothera | 2011 |
Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Common Bile Duct Neoplasms; Deoxyc | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemo | 2011 |
[A case of primary mucoepidermoid carcinoma arising from the common bile duct].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Cholangiopancreatography, Endoscop | 2011 |
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Chemoradiot | 2011 |
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, A | 2012 |
Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; B | 2012 |
Poorly differentiated adenocarcinoma with signet-ring cells of the Vater's ampulla, without jaundice but with disseminated carcinomatosis.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, | 2003 |
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
Topics: Adenocarcinoma; Ampulla of Vater; Animals; Cell Adhesion; Common Bile Duct Neoplasms; Deoxycytidine; | 2004 |
[Adjuvant arterial infusion chemotherapy for patients with biliary cancer].
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chem | 2004 |
Adjuvant chemo-radiotherapy in ampullary cancers.
Topics: Adult; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct N | 2005 |
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Chemotherapy, Adjuvant; Combined M | 2005 |
Early occurrence of chylothorax related to thoracic irradiation and concomitant chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chylothorax; Cispl | 2005 |
Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Analysis of Variance; Antimetabolites, Antineoplas | 2006 |
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti | 2007 |
Liver perfusion chemotherapy for selected patients at a high-risk of liver metastasis after resection of duodenal and ampullary cancers.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adj | 2007 |
Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Analysis of Variance; Antineoplastic Combined Chem | 2008 |
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineop | 1982 |
Combination chemotherapy for metastatic carcinoma of the ampulla of Vater--report of three cases.
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Common Bile Duct | 1984 |
[Indications and technic of percutaneous external biliary drainage].
Topics: Antineoplastic Agents; Bile; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cholestasis, | 1981 |
[A case of common bile duct cancer responding to MMC leucovorin, 5-FU, and UFT combination chemotherapy and radiation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Common Bile Duct Ne | 1996 |
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 | 1999 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; A | 2000 |
[Conformal therapy of locally advanced cholangiocarcinoma of the main bile ducts].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2002 |
[Biliary and pancreatic excretion of methotrexate (MTX) and 5-FU on the MTX/5-FU sequential therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile; Common Bile Duct Neoplasms; Drug Admini | 1990 |
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.
Topics: Activities of Daily Living; Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemothe | 1989 |